Age, Biography and Wiki

Charles Suckling was born on 24 July, 1920, is a British chemist. Discover Charles Suckling's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 93 years old?

Popular As N/A
Occupation N/A
Age 93 years old
Zodiac Sign Leo
Born 24 July, 1920
Birthday 24 July
Birthplace N/A
Date of death 31 October 2013
Died Place N/A
Nationality

We recommend you to check the complete list of Famous People born on 24 July. He is a member of famous with the age 93 years old group.

Charles Suckling Height, Weight & Measurements

At 93 years old, Charles Suckling height not available right now. We will update Charles Suckling's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Charles Suckling Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Charles Suckling worth at the age of 93 years old? Charles Suckling’s income source is mostly from being a successful . He is from . We have estimated Charles Suckling's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income

Charles Suckling Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

1920

Charles Walter Suckling (24 July 1920 – 31 October 2013) was a British chemist who first synthesised halothane, a volatile inhalational anaesthetic in 1951, while working at the Imperial Chemical Industries (ICI) Central Laboratory in Widnes.

He was born in Teddington, London in 1920, the son of Edward Ernest and Barbara (née Thomson) Suckling, and educated at Oldershaw Grammar School, Wallasey and Liverpool University.

1942

He worked, initially as a research chemist, for ICI from 1942 to 1982, becoming Deputy Chairman of Mond Division in 1969 and Chairman of Paints Division in 1972, finally being appointed General Manager of Research in 1977 (until retirement in 1982).

1946

He married Eleanor Margaret Watterson in 1946; they had two sons and a daughter.

1956

After Raventos established its pharmacological properties, it was given to Michael Johnstone, an anaesthetist in Manchester, England, who recognised its great advantages over the other anaesthetics available and established its first clinical trial in 1956.

This process of systematic study of chemical compounds with a set of pre-defined characteristics has been identified as one of the first examples of modern drug design.

Suckling, C. W. Some chemical and physical factors in the development of fluothane.

Br J Anaesth.

1957

1957 Oct;29(10):466-72.

O'Brien HD.

The introduction of halothane into clinical practice: the Oxford experience.

Anaesth.

Intensive Care.

1978

He was elected a Fellow of the Royal Society in 1978.

2006

2006 Jun;34 Suppl 1:27-32.

2013

He died on 31 October 2013.

At the time of Suckling's original research, the main anaesthetic gases in use were chloroform and diethyl ether, both of which had several serious drawbacks.

Ether was highly flammable, which was particularly dangerous in operating theatres as electrical equipment such as diathermy became more common.

Chloroform was toxic to the liver.

The halogenated alkanes (alkyl halides, also known as haloalkanes) in general, and in particular the fluorinated compounds were promising because they were volatile but not flammable.

Suckling had worked on such compounds extensively during World War II, when they were used in the production of high-octane aviation fuel, and in the purification of uranium-235.

He proceeded to synthesise a variety of fluorinated hydrocarbons before evaluating them for anaesthetic properties.

He liaised closely with clinicians, initially in setting target physicochemical properties for ideal agents and then later in evaluating the developed compounds.

Suckling first investigated halothane's anaesthetic action by experimenting on mealworms and houseflies, and then forwarded it to Jaume Raventos, a pharmacologist, for evaluation of anaesthesia in other animals.